SLC5A2 and type 2 diabetes mellitus: The sodium-glucose cotransporter 2 inhibitors (SGLT2i) were initially developed and approved to treat hyperglycemia in patients with T2D, but potent CV and kidney benefits were subsequently demonstrated in large-scale randomized trials.